KBC Group NV Purchases New Holdings in Clarivate PLC $CLVT

KBC Group NV purchased a new position in shares of Clarivate PLC (NYSE:CLVT) during the first quarter, Holdings Channel reports. The firm purchased 1,627,739 shares of the company’s stock, valued at approximately $4,118,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Cetera Investment Advisers grew its holdings in shares of Clarivate by 11.2% during the 2nd quarter. Cetera Investment Advisers now owns 26,034 shares of the company’s stock worth $112,000 after purchasing an additional 2,617 shares in the last quarter. California State Teachers Retirement System raised its stake in Clarivate by 0.9% in the second quarter. California State Teachers Retirement System now owns 303,147 shares of the company’s stock valued at $1,304,000 after purchasing an additional 2,788 shares in the last quarter. Envestnet Asset Management Inc. raised its stake in Clarivate by 3.9% in the third quarter. Envestnet Asset Management Inc. now owns 77,275 shares of the company’s stock valued at $296,000 after purchasing an additional 2,884 shares in the last quarter. IFP Advisors Inc lifted its position in Clarivate by 8.1% during the third quarter. IFP Advisors Inc now owns 41,426 shares of the company’s stock worth $170,000 after purchasing an additional 3,117 shares during the period. Finally, Hsbc Holdings PLC grew its stake in Clarivate by 4.3% during the second quarter. Hsbc Holdings PLC now owns 116,648 shares of the company’s stock worth $500,000 after buying an additional 4,792 shares in the last quarter. 85.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Wall Street Zen raised shares of Clarivate from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a research note on Wednesday, June 24th. Finally, Barclays boosted their price objective on shares of Clarivate from $2.40 to $2.50 and gave the company an “underweight” rating in a research report on Tuesday, July 7th. Four equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $2.98.

Clarivate Stock Performance

Clarivate stock opened at $1.95 on Friday. Clarivate PLC has a 12-month low of $1.66 and a 12-month high of $4.77. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 0.89. The business’s 50-day moving average price is $2.31 and its two-hundred day moving average price is $2.47. The stock has a market cap of $1.24 billion, a PE ratio of -9.26 and a beta of 1.38.

Clarivate (NYSE:CLVT) last posted its earnings results on Wednesday, April 29th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. The firm had revenue of $585.50 million during the quarter, compared to analysts’ expectations of $569.50 million. During the same quarter in the prior year, the business earned $0.14 earnings per share. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. As a group, analysts expect that Clarivate PLC will post 0.65 earnings per share for the current fiscal year.

Clarivate Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.